Tag Archives: Oncology

22Sep/24

Experts ensure that early detection and proper prevention are key to tackling the future challenges of cancer

Reasearch, , , , ,

MEDSIR, a leading company dedicated to advancing independent clinical research in oncology on an international level and part of Oncoclínicas & Co, the largest oncology treatment group in Latin America with significant strength in the clinical and outpatient setting, showcased its groundbreaking research at this year’s European Society for Medical Oncology (ESMO) Congress held in Barcelona. The company presented 12 new studies that address various types of cancer, marking a significant scientific milestone for MEDSIR. Continue reading

22Sep/24

Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players

Reasearch, , , , , ,

In the oncology world, there’s been plenty to celebrate recently, with cancer deaths falling by 33% in the last 30 years. However, there’s still a lot of work to do in the war on cancer, with the 2024 World Cancer Congress in Geneva highlighting several issues, such as artificial intelligence (AI), conflict zones and crisis care taking center stage at the gathering. Continue reading

17Sep/24

Experts ensure that early detection and proper prevention are key to tackling the future challenges of cancer

Lifestyle, , , , , ,

In the framework of the European Society of Medical Oncology (ESMO) congress, held in Barcelona from September 13th to 17th, MEDSIR, a company that is part of Oncoclínicas & Co, dedicated to promoting independent clinical research in oncology internationally, hosted an informational breakfast with key players in cancer research to discuss the present and future of breast and lung cancer treatments. Continue reading

28Aug/24

Johnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology Congress

Reasearch, , ,

Johnson & Johnson (NYSE: JNJ) announced today that 11 oral presentations from the Company’s industry-leading solid tumor portfolio and pipeline will be featured at the 2024 World Conference on Lung Cancer (WCLC) and the European Society for Medical Oncology (ESMO) 2024 Congress. Twenty-seven studies (23 company-sponsored and four investigator-initiated), including four late-breaking abstracts, will feature new data in lung, bladder, prostate, and colorectal cancers. Continue reading

28Aug/24

FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies

Reasearch, , , , , ,

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Food and Drug Administration (FDA) approval of its in vitro diagnostic (IVD) TruSight™ Oncology (TSO) Comprehensive test and its first two companion diagnostic (CDx) indications. This single test interrogates over 500 genes to profile a patient’s solid tumor, helping to increase the likelihood of identifying an immuno-oncology biomarker or clinically actionable biomarkers that enable targeted therapy options or clinical trial enrollment. Continue reading